SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Enterprises soars as its Pharma Solution division plan to invest $40 million in new technology

14 Jan 2015 Evaluate

Piramal Enterprises is currently trading at Rs. 869.10, up by 31.10 points or 3.71% from its previous closing of Rs. 838.00 on the BSE.

The scrip opened at Rs. 840.00 and has touched a high and low of Rs. 875.00 and Rs. 840.00 respectively. So far 5482 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 875.00 on 14-Jan-2015 and a 52 week low of Rs. 508.00 on 14-Mar-2014.

Last one week high and low of the scrip stood at Rs. 844.00 and Rs. 810.00 respectively. The current market cap of the company is Rs. 15038.87 crore.

The promoters holding in the company stood at 52.90 % while Institutions and Non-Institutions held 30.51 % and 16.59 % respectively.

Piramal Enterprises’ Pharma Solution division, a global leader in contract development and manufacturing is planning to invest $40 million in new equipment and next generation technologies.

The recent investments include areas such as Anti-body Drug Conjugation (ADC), Advanced Flow Reactor (ARF) and Biocatalysis Centre of Excellence systems. In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure.

Piramal Pharma Solutions is an integrated solutions provider offering comprehensive range of services across the drug lifecycle. With a successful performance record of over four-decade in API supply (active pharmaceutical ingredients), drug products, drug discovery services, and with supply facilities in North America, Europe and Asia, it has established itself as a global market leader.

 

Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×